NO20005621L - Nye medikamentkombinasjoner - Google Patents
Nye medikamentkombinasjonerInfo
- Publication number
- NO20005621L NO20005621L NO20005621A NO20005621A NO20005621L NO 20005621 L NO20005621 L NO 20005621L NO 20005621 A NO20005621 A NO 20005621A NO 20005621 A NO20005621 A NO 20005621A NO 20005621 L NO20005621 L NO 20005621L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- new drug
- drug combinations
- disorder
- anxiety
- Prior art date
Links
- 239000002547 new drug Substances 0.000 title 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 2
- 208000019906 panic disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002508 pindolol Drugs 0.000 abstract 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 1
- 229960003770 reboxetine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8486098P | 1998-05-08 | 1998-05-08 | |
PCT/US1999/006523 WO1999058130A1 (fr) | 1998-05-08 | 1999-04-14 | Nouvelles combinaison medicamenteuses d'un inhibiteur du recaptage de la noradrenaline (nari), de preference de la reboxetine, et de pindolol |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20005621L true NO20005621L (no) | 2000-11-07 |
NO20005621D0 NO20005621D0 (no) | 2000-11-07 |
Family
ID=22187677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005621A NO20005621D0 (no) | 1998-05-08 | 2000-11-07 | Nye medikamentkombinasjoner |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1075264B1 (fr) |
JP (1) | JP2002514601A (fr) |
KR (1) | KR20010052319A (fr) |
CN (1) | CN1300217A (fr) |
AT (1) | ATE283694T1 (fr) |
AU (1) | AU764579B2 (fr) |
BR (1) | BR9909559A (fr) |
CA (1) | CA2326105A1 (fr) |
DE (1) | DE69922367T2 (fr) |
EA (1) | EA003469B1 (fr) |
ES (1) | ES2232128T3 (fr) |
HU (1) | HUP0101341A3 (fr) |
IL (1) | IL139211A0 (fr) |
NO (1) | NO20005621D0 (fr) |
NZ (1) | NZ508035A (fr) |
PL (1) | PL345351A1 (fr) |
PT (1) | PT1075264E (fr) |
SI (1) | SI1075264T1 (fr) |
SK (1) | SK14502000A3 (fr) |
TR (1) | TR200003262T2 (fr) |
WO (1) | WO1999058130A1 (fr) |
ZA (1) | ZA200005301B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1500395B1 (fr) * | 1999-07-01 | 2006-03-08 | Pharmacia & Upjohn Company LLC | Reboxétine pour traiter les fibromyalgies et d'autres troubles somatoformes |
PT1632234E (pt) | 1999-07-01 | 2007-07-09 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica |
US20040102440A1 (en) * | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
AU2003268026A1 (en) | 2002-07-30 | 2004-02-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
EP1723957A3 (fr) | 2002-12-27 | 2013-01-23 | Otsuka Pharmaceutical Co., Ltd. | Dérivés de carbostyrile et inhibiteurs de réabsorption de la sérotonine pour le traitement des troubles de l'humeur |
AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
EP2429514A1 (fr) * | 2009-05-13 | 2012-03-21 | Sunovion Pharmaceuticals Inc. | Compositions comprenant de la transnorsertraline et des agonistes/antagonistes du récepteur 1a de la sérotonine et leurs applications |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2134038C (fr) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentialisation des effets de medicaments |
ES2145977T3 (es) * | 1995-08-16 | 2000-07-16 | Lilly Co Eli | Potenciacion de la respuesta de la serotonina. |
-
1999
- 1999-04-14 HU HU0101341A patent/HUP0101341A3/hu unknown
- 1999-04-14 TR TR2000/03262T patent/TR200003262T2/xx unknown
- 1999-04-14 PL PL99345351A patent/PL345351A1/xx not_active Application Discontinuation
- 1999-04-14 SK SK1450-2000A patent/SK14502000A3/sk unknown
- 1999-04-14 AU AU35460/99A patent/AU764579B2/en not_active Ceased
- 1999-04-14 IL IL13921199A patent/IL139211A0/xx not_active IP Right Cessation
- 1999-04-14 CA CA002326105A patent/CA2326105A1/fr not_active Abandoned
- 1999-04-14 PT PT99917309T patent/PT1075264E/pt unknown
- 1999-04-14 BR BR9909559-9A patent/BR9909559A/pt not_active Application Discontinuation
- 1999-04-14 WO PCT/US1999/006523 patent/WO1999058130A1/fr not_active Application Discontinuation
- 1999-04-14 AT AT99917309T patent/ATE283694T1/de not_active IP Right Cessation
- 1999-04-14 JP JP2000547981A patent/JP2002514601A/ja not_active Withdrawn
- 1999-04-14 EP EP99917309A patent/EP1075264B1/fr not_active Expired - Lifetime
- 1999-04-14 SI SI9930716T patent/SI1075264T1/xx unknown
- 1999-04-14 ES ES99917309T patent/ES2232128T3/es not_active Expired - Lifetime
- 1999-04-14 KR KR1020007012418A patent/KR20010052319A/ko not_active Application Discontinuation
- 1999-04-14 DE DE69922367T patent/DE69922367T2/de not_active Expired - Fee Related
- 1999-04-14 NZ NZ508035A patent/NZ508035A/xx unknown
- 1999-04-14 EA EA200001162A patent/EA003469B1/ru not_active IP Right Cessation
- 1999-04-14 CN CN99805216A patent/CN1300217A/zh active Pending
-
2000
- 2000-09-29 ZA ZA200005301A patent/ZA200005301B/en unknown
- 2000-11-07 NO NO20005621A patent/NO20005621D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR9909559A (pt) | 2000-12-19 |
EA003469B1 (ru) | 2003-06-26 |
ATE283694T1 (de) | 2004-12-15 |
WO1999058130A1 (fr) | 1999-11-18 |
EP1075264A1 (fr) | 2001-02-14 |
JP2002514601A (ja) | 2002-05-21 |
HUP0101341A2 (hu) | 2001-08-28 |
CN1300217A (zh) | 2001-06-20 |
PL345351A1 (en) | 2001-12-17 |
AU764579B2 (en) | 2003-08-21 |
SI1075264T1 (en) | 2005-06-30 |
AU3546099A (en) | 1999-11-29 |
KR20010052319A (ko) | 2001-06-25 |
PT1075264E (pt) | 2005-01-31 |
EA200001162A1 (ru) | 2001-04-23 |
ZA200005301B (en) | 2001-10-01 |
DE69922367D1 (de) | 2005-01-05 |
HUP0101341A3 (en) | 2006-07-28 |
DE69922367T2 (de) | 2005-12-22 |
ES2232128T3 (es) | 2005-05-16 |
IL139211A0 (en) | 2001-11-25 |
CA2326105A1 (fr) | 1999-11-18 |
SK14502000A3 (sk) | 2001-05-10 |
EP1075264B1 (fr) | 2004-12-01 |
NZ508035A (en) | 2004-02-27 |
TR200003262T2 (tr) | 2001-03-21 |
NO20005621D0 (no) | 2000-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sareen et al. | A review of the epidemiology and approaches to the treatment of social anxiety disorder | |
Shulman et al. | Current place of monoamine oxidase inhibitors in the treatment of depression | |
Ozyalcin et al. | The efficacy and safety of venlafaxine in the prophylaxis of migraine | |
Brunello et al. | Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment | |
CY1124111T1 (el) | Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων | |
RS27704A (en) | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | |
NO20100333L (no) | Behandling av nevrotiske forstyrrelser | |
AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
NO20052420L (no) | Farmakologisk behandling av sovnapn±. | |
NO20005621L (no) | Nye medikamentkombinasjoner | |
ATE447403T1 (de) | Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen | |
NO20070914L (no) | Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander | |
TNSN05131A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
Sood et al. | Diagnosis and treatment of pathologic gambling | |
HUP0402619A2 (hu) | Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására | |
NO20061425L (no) | Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin | |
WO2002040006A3 (fr) | Traitement de troubles anxieux | |
MA27538A1 (fr) | Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol | |
HUP0101748A2 (hu) | Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására | |
NO20085172L (no) | 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst | |
AU2002347984A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
DE69910242D1 (de) | Verwendung eines Nikotin-Rezeptor Agonisten zur Herstellung eines Medikaments zur Behandlung von Zwangsneurosen | |
PT1282414E (pt) | Compostos derivados de felbamato para o tratamento da dor neuropatica | |
NO20061427L (no) | Kombinasjonen av en serotonin-reoppttaksinhibitor og amoxapin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |